By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them. You can change your Cookie Settings at any time but parts of our site will not function correctly without them.

Reject
United Kingdom | EnglishEN

Current country and language: United KingdomUnited Kingdom | English (EN)

ChinaChina
GermanyGermany
IrelandIreland
ItalyItaly
SpainSpain
United KingdomUnited Kingdom

YOU ARE LEAVING THE CURRENT LANGUAGE


Completion of Acquisition of Vamousse®

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Completion of acquisition of Vamousse®

On 4 December 2017 Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, had entered into an agreement to acquire the worldwide rights to Vamousse from TyraTech Inc (AIM: TYR and TYRU) (the "Acquisition"). 

Further to Tyratech's announcement on 27 December 2017 that its shareholders have approved the Acquisition, Alliance is pleased to announce that it has today completed the Acquisition.

Alliance is also pleased to announce the appointment of Amanda Sicvol as Country Manager for its newly created US affiliate.  Amanda has been instrumental in the commercial success of Vamousse to date, having worked for Tyratech for four years. She brings significant expertise and considerable knowledge of the Vamousse brand. 

John Dawson, Alliance Pharma's Chief Executive Officer, commented: "The completion of this acquisition provides Alliance a third International star brand with best in class technology. There is also real potential for further growth through our substantial global network of distributors. We are delighted to welcome Amanda to Alliance to establish our presence in the US, the largest consumer healthcare market in the world."

For further information: 

Alliance Pharma plc                                     + 44 (0) 1249 466966
John Dawson, Chief Executive Officer
Peter Butterfield, Deputy Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk 
 
Buchanan                                                       + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
 
Numis Securities Limited                                + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock 
 
Investec Bank plc                                               +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Rob Baker

 
Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

By clicking "Yes" below, you hereby confirm that you are not accessing
the information provided on this website from the United States of America.